Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Clinical and Radiological Markers of Extra-Motor Deficits in Amyotrophic Lateral Sclerosis.

Author information

Affiliations

  • 1. First Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
      Authors
    • Christidi F 1
    • Rentzos M 1
    • Evdokimidis I 1
    (3 authors)
  • 2. Second Department of Radiology, University General Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece.
      Authors
    • Karavasilis E 2
    • Kelekis N 2
    (2 authors)
  • 3. Computational Neuroimaging Group, Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland.
      Authors
    • Bede P 3
    (1 author)

ORCIDs linked to this article

Frontiers in Neurology, 22 Nov 2018, 9:1005
https://doi.org/10.3389/fneur.2018.01005 PMID: 30524366 PMCID: PMC6262087

Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

Amyotrophic lateral sclerosis (ALS) is now universally recognized as a complex multisystem disorder with considerable extra-motor involvement. The neuropsychological manifestations of frontotemporal, parietal, and basal ganglia involvement in ALS have important implications for compliance with assistive devices, survival, participation in clinical trials, caregiver burden, and the management of individual care needs. Recent advances in neuroimaging have been instrumental in characterizing the biological substrate of heterogeneous cognitive and behavioral deficits in ALS. In this review we discuss the clinical and radiological aspects of cognitive and behavioral impairment in ALS focusing on the recognition, assessment, and monitoring of these symptoms.

Free full text 

Logo of frontneurologyLink to Publisher's site
Front Neurol. 2018; 9: 1005.
Published online 2018 Nov 22. https://doi.org/10.3389/fneur.2018.01005
PMCID: PMC6262087
PMID: 30524366

Clinical and Radiological Markers of Extra-Motor Deficits in Amyotrophic Lateral Sclerosis

Foteini Christidi,1,* Efstratios Karavasilis,2 Michail Rentzos,1 Nikolaos Kelekis,2 Ioannis Evdokimidis,1 and Peter Bede3
Author information Article notes Copyright and License information Disclaimer

Abstract

Amyotrophic lateral sclerosis (ALS) is now universally recognized as a complex multisystem disorder with considerable extra-motor involvement. The neuropsychological manifestations of frontotemporal, parietal, and basal ganglia involvement in ALS have important implications for compliance with assistive devices, survival, participation in clinical trials, caregiver burden, and the management of individual care needs. Recent advances in neuroimaging have been instrumental in characterizing the biological substrate of heterogeneous cognitive and behavioral deficits in ALS. In this review we discuss the clinical and radiological aspects of cognitive and behavioral impairment in ALS focusing on the recognition, assessment, and monitoring of these symptoms.

Keywords: amyotrophic lateral sclerosis, extra-motor involvement, cognition, behavior, neuropsychological deficits, neuroimaging

Introduction

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND), a progressive neurodegenerative condition defined by concomitant lower and upper motor neuron degeneration (1). Motor symptoms include muscle weakness, fasciculations, cramps, as well as spasticity and brisk reflexes that accrue to considerable limb and bulbar disability over time, and eventually respiratory failure (1). The identification of TAR DNA-binding protein 43 (TDP-43) positive ubiquitinated cytoplasmic inclusions in almost all patients with ALS and more than half of patients with frontotemporal dementia (FTD) has placed ALS on the so-called “ALS-FTD continuum,” highlighting the considerable clinical, pathophysiological, and neuroimaging overlap between the two neurodegenerative conditions (2).

Although mentioned in early descriptions of ALS (3, 4), cognitive and behavioral deficits and frank dementia were previously considered atypical of ALS. It is not until the end of the twentieth century that clinical and research interest shifted to the extra-motor features of ALS and it has been gradually recognized as a genuine multisystem disease (5–8).

Neuropsychological deficits in ALS range from mild impairment to full-blown FTD. Up to 65% of ALS patients exhibit some cognitive or behavioral impairment (9–12) and 6–15% of sporadic ALS patients meet diagnostic criteria for FTD (10–13). While hexanucleotide repeat expansions in C9ORF72 are often associated with ALS-FTD (14), extra-motor symptoms are not unique to this mutation and extra-motor neuroimaging findings can also be readily identified in a significant proportion of C9 negative patients (15, 16). The early recognition of extra-motor involvement in ALS is crucial due to its impact on functional decline (17), survival (18), compliance with assistive devices (19), decision-making, and engagement in end-of-life and legal decisions (20).

Cognitive dysfunction

Much attention has been initially focused on executive dysfunction (21, 22) in ALS which has been gradually complemented by the characterization of language (23, 24), memory (25, 26), praxis (27), and theory of mind deficits (28) (Table ​(Table1).1). Population-based studies have confirmed distinct cognitive phenotypes without executive impairment (10, 11, 29).

Table 1

Most characteristic neuropsychological deficits in ALS categorised per cognitive domain.

Main cognitive domainsTarget processes/main deficitsRepresentative studies (First author, year, sample size ALS/Control)
Executive functionsVerbal fluencyLudolph, 1992 (21/12); Kew, 1993 (16/16); Abrahams, 1995 (12/6); Massman, 1996 (146/–); Abrahams, 1996 (12/6); Abrahams, 1997 (52/28); Frank, 1997 (74/56); Rakowicz, 1998 (18/24); Abrahams, 2000 (21/25); Lomen- Hanagasi, 2002 (20/13); Hoerth, 2003 (44/–); Abrahams, 2004 (28/18); Abrahams, 2005 (20/18); Pinkhardt, 2008 (20/20); Wicks, 2009 (41/35); Witgert, 2010 (225/–); Stukovnik, 2010 (22/21); Phukan, 2012 (160/110); Taylor, 2013 (51/35)
Concept formation and mental flexibilityAbrahams, 1996 (12/6); Massman, 1996 (146/-); Abrahams, 1997 (52/28); Frank, 1997 (74/56); Evdokimidis, 2002 (51/28); Moretti, 2002 (14/15); Lomen-Hoerth, 2003 (44/-); Schreiber, 2005 (52/-); Libon, 2012 (41/25); Zalonis, 2012 (48/47); Taylor, 2013 (51/35)
Mental set shiftingHartikainen, 1993 (24/26); Hanagasi, 2002 (20/13); Kilani, 2004 (18/19); Witgert, 2010 (225/–)
Response inhibition and attentional controlAbrahams, 1997 (52/28); Frank, 1997 (74/56); Hanagasi, 2002 (20/13); Moretti, 2002 (14/15); Lomen-Hoerth, 2003 (44/-); Sterling, 2010 (355/-); Christidi, 2012 (22/22); Phukan, 2012 (160/110); Zalonis, 2012 (48/47)
Working memoryAbrahams, 1997 (52/28); Rakowicz, 1998 (18/24); Abrahams, 2000 (21/25); Hanagasi, 2002 (20/13); Abrahams, 2004 (28/18); Abrahams, 2005 (20/18); Lillo, 2012 (20/18)
Reasoning and coordinating rules using ecologically valid measuresMeier, 2010 (18/18); Stukovnik, 2010 (22/21)
MemoryEpisodic memory encodingHanagasi, 2002 (20/13); Mantovan, 2003 (20/20); Christidi, 2012 (22/22)
Episodic memory retrievalHanagasi, 2002 (20/13); Ringholz, 2005 (279/129); Christidi, 2012 (22/22); Elamin, 2013 (186/120); Raaphorst, 2015 (26/21)
Episodic memory consolidation/recognitionMachts, 2014 (40/40); Christidi, 2012 (22/22)
Visual delayed recallRingholz, 2005 (279/129)
Semantic memoryHervieu-Begue, 2016 (15/-)
LanguageVerb naming and action verb processingBak, 2001 (6/20); Grossman, 2008 (34/25); York, 2014 (36/13); Papeo, 2015 (21/14)
Grammatical errorsAsh, 2015 (26/19); Tsermentseli, 2015 (26/26)
Phonemic and semantic paraphasiasRoberts-South, 2012 (16/12); Tsermentseli, 2015 (26/26)
Establishing and adhering to the main topic of conversationsAsh, 2015 (26/19); Bambini, 2016 (33/33)
Narrative speech pausesYunusova, 2016 (85/33)
Syntactic processing/comprehensionYoshizawa, 2014 (25/–); Tsermentseli, 2015 (26/26); Kamminga, 2016 (35/23)
PraxisConstructive apraxiaAbrahams, 1997 (52/28)
Orofacial apraxiaLobo, 2013 (1/–)
Speech apraxiaDuffy, 2007 (7/–)
Respiratory apraxiaPinto, 2007 (1/–)
Social cognitionTheory of mindMeier, 2010 (18/18); Girardi, 2011 (19/20); Burke, 2016 (59/59)
Emotional processing and ability to recognize emotional facial expressionsPalmieri, 2010 (9/10); Girardi, 2011 (19/20); Crespi, 2014 (22/55); Savage, 2014 (29/30); Andrews, 2017 (33/22)
Ability to describe intentions and feelings of othersGibbons, 2007 (16/16); Staios, 2013 (35/30); Cerami, 2014 (20/56)
EmpathyGirardi, 2011 (19/20); Cerami, 2014 (20/56)
Social inferencesStaios, 2013 (35/30); Savage, 2014 (29/30)
BehaviorApathyGrossman, 2007 (45/–); Chio, 2010 (70/–); Witgert, 2010 (225/–); Girardi, 2011 (19/20); Radakovic, 2016 (83/83)
DisinhibitionGrossman, 2007 (45/–); Terada, 2011 (24/–)
Pathological crying and laughingMcCullagh, 1999 (18/10); Palmieri, 2009 (32/39); Olney, 2011 (35/–); Brooks, 2013 (9/–); Floeter, 2014 (22/28); Christidi, 2018 (56/25)

ALS, amyotrophic lateral sclerosis.

Executive dysfunction

Executive dysfunction is the most commonly cited facet of cognitive impairment in ALS. Executive function however is an umbrella term encompassing several relatively distinct higher-order processes, such as planning, organization, goal-directed activity, working memory, initiation, behavioral regulation, and inhibitory control, as well as situation-appropriate decision-making on the basis of projected positive and negative outcomes in novel, complex or ambiguous situations (30). In addition, tests of verbal (i.e., phonemic and semantic/category) and figural/design fluency are also often conceptualized as proxies of executive performance (31).

Verbal fluency impairment has been consistently reported in ALS (11, 22, 24, 27, 32–46). Coexisting phonemic and semantic fluency dysfunction or phonemic fluency deficits alone are often linked to executive dysfunction, while isolated semantic fluency deficits are associated with impaired semantic memory processing. Semantic (24, 34, 40, 44, 46, 47) and figural (34, 46) fluency are not typically impaired in ALS. A verbal fluency index has been proposed and is now widely utilized to account for patients' motor disability (32, 48). Other executive processes are also affected in ALS, such as concept formation and mental flexibility (24, 27, 33, 35, 36, 41, 49–53) which is typically examined by the Wisconsin Card Sorting Test or the Dellis-Kaplan Executive Function System Card Sorting Test (31). However, not all neuropsychology studies corroborate these findings (34, 38, 39, 45, 46, 54–56). Several studies have specifically evaluated mental set shifting ability in ALS using the Trail Making Test; most of them identifying considerable dysfunction (37, 42, 47, 55, 57), while others have not captured such deficits (58, 59). Response inhibition and attentional control are typically examined by the Stroop test, and are often impaired in ALS (11, 27, 35–37, 51, 53, 57, 60), but unaffected cohorts have also been reported (39, 40, 44, 49). ALS patients also often exhibit difficulties in maintaining, manipulating and retrieving information relying on working memory (27, 32, 34, 37, 43, 46, 61), but preserved working memory has also been observed (39, 44, 51, 54, 55, 58, 62). Subtle deficits in reasoning and coordinating rules have been found using ecologically valid measures of executive functions (44, 63).

Memory deficits

Following inconsistent initial reports, memory dysfunction in ALS has received increasing attention recently (7, 64). While autobiographic memory seems to be preserved in ALS (65), semantic memory is often affected (66). Episodic memory is the most commonly evaluated memory domain in ALS, typically tested by list-learning tests, associate-learning tests, prose memory, as well as visual memory tests (7). Several studies have reported mild to moderate episodic memory impairments which are often interpreted as the corollary of underlying executive deficits (27, 35, 37, 39, 41, 67–69). Memory impairment in ALS is rarely identified in isolation (11), but using data-driven taxonomy approaches a subgroup of patients may show non-executive memory dysfunction (29). Several studies have found impaired encoding (37, 60, 68), retrieval (12, 17, 37, 60, 70) consolidation and recognition (26, 60), although recognition deficits in ALS are not universally recognized (11, 37, 41). Visual memory dysfunction has also been noted in ALS (12), although visual recall is typically less affected than delayed verbal recall (7). Neuroimaging studies have contributed to the characterization of ALS-associated memory impairment highlighting mesial temporal lobe involvement irrespective of frontal lobe pathology (64).

Language deficits

Language deficits in ALS have traditionally attracted less attention compared to other cognitive domains and have been mostly appraised in association with ALS-FTD (7, 23, 71, 72). However, language dysfunction is increasingly recognized as a core feature of ALS and has been consistently detected in patients without executive dysfunction (24, 29, 73). Patients with ALS show impaired syntactic processing (74), deficits in verb naming and action verb processing (75, 76). Selective impairment in action knowledge (77) has been directly associated with motor cortex degeneration (78) suggesting a link between action execution and action conceptualization (79). Grammatical errors such as incomplete utterances (73, 74) and omission of determiners (73) have been reported in ALS and seem to be dissociable from the patients' motor and executive deficits (73). Phonemic and semantic paraphasias have also been reported (74, 80). Patients with ALS may find narrative discourse particularly challenging due to difficulties to establish (81) and adhere to the main topic of conversation (73, 81). Frequent pauses are another key characteristic of narrative speech in ALS in both demented and non-demented ALS cohorts (82). Syntactic comprehension deficits have also been detected in up to 72% of patients with ALS (83, 84).

Visuo-perceptive and visuo-constructive deficits

Visuo-perceptive and visuo-constructive functions are seldom specifically examined in ALS. Existing studies tend to focus on visuospatial memory measures and often fail to reach definite conclusions (37, 41, 46, 47, 85). Based on large meta-analyses, these domains are not significantly affected in ALS (7). The relative absence of visuo-perceptual deficits is further supported by the lack of reports on Balint's syndrome in ALS and is consistent with limited occipital involvement on neuroimaging (86) and pathology (87). While praxis deficits are also rarely reported in ALS (27), orofacial (88), speech (89), and respiratory (90) apraxia have been sporadically reported.

Social cognition deficits

Social cognition refers to a diverse set of cognitive skills that allow humans to understand themselves, interact with and understand others and are crucial to adopt situation-appropriate, goal-directed behaviors in everyday social interactions (91). Despite considerable variations, deficits in theory of mind, empathy, social perception, social behavior are now recognized as key elements of the ALS-associated cognitive profile (7, 28, 92). It is however still unclear if these deficits are linked to executive dysfunction (29, 93–98) or may be related to non-executive domains, such as episodic memory function and visuospatial abilities (99). Patients with ALS may also exhibit impaired emotional processing and ability to interpret emotional facial expressions, especially with comorbid FTD (96, 100–102). Impairments in complex facial affect recognition, affective prosody recognition and cross-modal integration have also been found in non-demented ALS cohorts (103). Multiple subcomponents of theory of mind seem to be affected in ALS, including the ability to describe the intentions and feelings of others (95, 98, 104), to recognize and provide explanations for social “faux pas” (63) and evaluate object preferences based on the interpretation of eye gaze direction (96, 105). Loss of empathy (96), impaired emotional empathy attribution (95), and erroneous social inferences (98, 100) have also been reported in non-demented ALS cohorts.

Behavioral deficits

The clinical link between ALS and FTD is exemplified by overlapping behavioral changes which are similar to those observed in behavioral variant of FTD (106). These deficits are typically identified through a structured clinical interview with the caregivers or through validated questionnaires. Perseveration, apathy and disinhibition are the most commonly reported behavioral alterations, followed by loss of disease insight, indifference, loss of interest, aggression, irritability, and lability (107).

Apathy is the most commonly reported behavioral symptom in non-demented ALS (42, 45, 96, 108, 109), which used to be assessed by generic behavioral instruments, such as the Frontal Systems Behavior Scale (110) and the Frontal Behavioral Inventory (111), until the development of ALS-specific scales, such as the Dimensional Apathy Scale (112) which appraises initiation, executive and emotional apathy. Initiation apathy is thought to be particularly prevalent in ALS (113). ALS patients with apathy may require prompts to initiate or follow through with a task, including self-care, feeding, and taking medications. They may appear poorly motivated, aloof or uninterested. Apathy may impact of rehabilitation, hamper gait initiation, and curb communication efforts especially in the presence of bulbar impairment. It can be mistaken for low mood, depression and withdrawal by inexperienced observers. Disinhibition is more readily identified and reported by caregivers, and can precede (108) or follow (114) motor disability. Disinhibited behavior can manifest in rude, offensive, flirtatious comments, puns, “Witzelsucht” often violating social norms, personal space and may result in careless or impulsive decisions. Purchasing expensive items on a whim, hoarding, compulsive behavior, overeating, and developing a preference for sweets have also been reported (115).

Hallucinations have been reported by several groups (116–119) and are sometimes associated with the C9orf72 genotype. Symptomatic treatment includes the judicious use of small dose atypical antipsychotics, if necessary.

Patients with pseudobulbar affect or pathological crying and laughing exhibit sudden situation-inappropriate emotional responses (120–122) which may have a negative impact on their quality of life (123) and lead to social isolation or social stigma. It is most commonly associated with UMN-type bulbar dysfunction (124), but frontal abnormalities, executive dysfunction, basal ganglia pathology and impaired cerebellar gating mechanisms have also been linked this symptom (27, 122, 125–128).

Insights from neuroimaging

Neuroimaging techniques provide optimal non-invasive tools to characterize extra-motor pathology in ALS underpinning cognitive and behavioral deficits and also permit exploratory correlations with clinical measures (129, 130).

Structural imaging

Voxel based morphometry (VBM) and surface-based morphometry (SBM) are reproducible, validated and widely-used pipelines that use high resolution 3D T1-weighted MR images to identify focal GM alterations. Beyond the consensus on motor cortex atrophy (131), many studies also detect multifocal frontotemporal and parietal GM changes (132). GM abnormalities have also been identified in subcortical structures (133), such as the hippocampus (134–136), amygdala (137, 138), thalamus (134, 135, 139, 140), and insula (141, 142). Reduced GM density in occipital (139, 143–145) and cerebellar (139, 146) regions is less commonly reported. GM alterations in extra-motor areas have been linked to structure-specific cognitive and behavioral deficits in ALS (147, 148). Recent studies have highlighted extra-motor cortical changes in ALS patients without overt cognitive impairment (134, 135, 146, 149, 150). The anatomical patterns of extra-motor gray matter involvement in ALS further support the notion of the ALS-FTD continuum (72).

White matter integrity in ALS is most commonly evaluated by diffusion tensor imaging (DTI). Reduced fractional anisotropy and increased axial and radial diffusivity in the corticospinal tracts and corpus callosum are hallmark features of ALS (151, 152). Extra-motor white matter pathology has been consistently detected in frontal (139, 153–160), temporal (53, 154, 161), cingular (162), parahippocampal (25, 157, 160), insular (160), thalamic (141, 159, 163), and cerebellar regions (86, 146, 164). Similarly to gray matter analyses, extra-motor white matter involvement has also been identified in ALS patients without overt cognitive impairment (146).

Metabolic imaging

MR spectroscopy in ALS has consistently revealed decreased N-acetyl aspartate (NAA)/choline and NAA/creatine ratios in motor regions (165–167), but whole brain spectroscopy also detected extra-motor NAA reductions in frontal, parietal, thalamic and occipital areas (168, 169).

Most positron emission tomography (PET) studies in ALS use 18F-FDG PET, but TSPO, GABAA (11C-flumazenil) and 5-HT1A receptor (11C-WAY100635) radioligands have also been utilized (170). Hypometabolism in motor regions is a characteristic FDG-PET finding in ALS (171–174), but extra-motor changes in dorsolateral prefrontal, orbitofrontal, anterior frontal, anterior temporal, fusiform, and occipital regions have also been reported (171–174). Frontotemporal hypometabolism has been linked to cognitive performance (22, 39, 172), is thought to precede atrophy (175) and has been linked to shorter survival (176). There is also evidence of hypermetabolism in the hippocampus, amygdala midbrain, pons and cerebellum (173, 174, 177). PET imaging has identified microglial activation in frontotemporal, thalamic, midbrain, and pontine regions suggestive of extra-motor inflammation (178–181). Widespread reduction of 11C-Flumazenil binding to GABAA in sporadic ALS has been interpreted as inhibitory dysfunction (182) and is regarded as a one of cornerstones of ALS pathogenesis (183). Reduced serotonin receptor binding has also been reported in ALS using the 11C-WAY100635 radio-ligand (184).

Functional imaging

Resting state fMRI enables the assessment of functional connectivity between different brain regions by evaluating synchronized neuronal activity at rest. Reduced (185–189) and increased (183, 190) functional connectivity have both been reported in sensorimotor networks of ALS patients which may be explained by the different sub-regions evaluated (191–193) and also by the inclusion of patients in different disease-stages. Similarly, both reduced and increased functional connectivity alterations have been reported in extra-motor areas which mediate cognitive and behavioral functions (187, 188, 193, 194). The functional connectivity of the default mode network (DMN) has been reported to be both decreased (187, 189, 193) and increased (193, 195). Increased functional connectivity has been detected in the DMN using graph theory-based analyses (196). Increased (193) and decreased (186, 189, 193) fronto-parietal network integrity has been both reported. Reduced “executive control network” (middle frontal cortex) and “salience network” (medial prefrontal cortex, insula) connectivity has been described in ALS cohorts without dementia (189). Increased connectivity in ALS has either been interpreted as evidence of attempted compensation for structural degeneration (197, 198) or proof of inhibitory dysfunction (183, 190, 199).

Task-based fMRI studies in ALS have consistently revealed the recruitment of pre- and supplementary motor regions when executing motor tasks. Additional activation has also been observed in areas associated with motor learning areas, such as the basal ganglia and cerebellum (200, 201). Despite difference in study protocols, an activation shift to premotor (202, 203), temporal and parietal regions (203–205) has been often noted. Cognitive paradigms have been particularly helpful in capturing frontotemporal network alterations. Impaired verbal fluency was linked to reduced frontotemporal, parietal, and cingulate activation in non-demented ALS patients (46). Impaired frontal inhibitory control was confirmed by a number of fMRI paradigms, such as Stroop, negative priming, antisaccade tasks, go/no-go tasks etc. Increased activation during the Stroop paradigm and decreased activation in negative priming conditions has been reported mostly in left hemispheric regions (206). Increased activation in supplementary and frontal eye fields and reduced activation in dorsolateral prefrontal cortex have been noted in antisaccade tasks (207). Furthermore, in go/no-go paradigms, ALS patients show increased inhibition-related activation in frontal and basal ganglia regions and increased execution-related activity in contralateral sensorimotor regions (208). Few studies have specifically examined the functional correlates of social cognition to date. Patients with ALS tend to show increased activation compared to healthy participants in the right supramarginal, anterior cingulate and bilateral dorsolateral prefrontal cortex in response to socio-emotional stimuli (56, 209). The combined use of motor and memory tasks on fMRI enables the longitudinal characterization of divergent motor and extra-motor functional changes. Increased motor activation was found in ALS compared to controls at baseline, which has decreased on the follow-up assessment, suggestive of failing compensation. Contrary to the functional motor changes, hippocampal activation increased on follow-up when novel stimuli was presented (210).

Relevance to clinical care

The detection (48), expert evaluation (11), categorization (211), and follow-up (17) of extra-motor deficits in ALS is crucially important for individualized patient care. While screening tests (Table ​(Table2)2) are useful for the detection of gross deficits, expert review by neuropsychologists is indicated for accurate patient classification. Adherence to treatment, compliance with assistive devices, participation in clinical trials, making informed financial and end-of-life decisions, choices in participating in non-licensed treatments are just some of the aspects of a patient journey which may be significantly affected by cognitive or behavioral deficits (19, 212). Cognitive impairment in ALS is widely regarded as a negative prognostic indicator and linked to reduced survival (17, 18, 213). Neuropsychological deficits in ALS are thought to be associated with increased caregiver burden (214, 215) and reduced quality of life (216). The recognition of the far-reaching effects of neuropsychological deficits on nearly all aspects of ALS care, caregiver support, resource allocation, and prognosis, led to the inclusion of specialist neuropsychologists as core members of ALS multidisciplinary teams worldwide (217, 218). The careful evaluation of motor deficits which are not directly linked to the corticospinal axis and are not reflected in the ALSFRS-R score, such as extra-pyramidal deficits are also crucial (219). Extra-pyramidal deficits may contribute to falls and gait impairment and are increasingly investigated in neuroimaging studies (220, 221). These symptoms may present early in the course of the disease, and contribute the clinical heterogeneity of the condition (220, 222). Postural instability and rigidity may be associated with other extra-motor deficits, and potentially linked to poor survival (205, 223). There is some controversy about the chronology of motor and extra-motor involvement in ALS. Extra-motor manifestations, such as dementia (224, 225), psychiatric features (226), and extra-pyramidal symptoms (227) have been reported to precede motor symptoms in some cases, and there is also compelling evidence of early extra-motor pathology in cognitively normal ALS patients (134, 135, 146).

Table 2

ALS-specific instruments to screen for cognitive and behavioral changes at baseline and during the course of the disease.

Screening instrumentDuration of administrationCognitive and behavioral domains examinedParallel forms for longitudinal assessmentValidation in non-English speaking populations
Edinburgh Cognitive and Behavioral ALS Screen (ECAS)15–20 minExecutive functions, Social cognition,
Language,
Visuoconstruction,
Memory
Behavioral changes (including psychotic symptoms)		YesAmerican-English; Belgium; Chinese; Croatian; Czech; Dutch; French; German; Swiss-German; Greek; Hebrew; Italian; Japanese; Norwegian; Polish; Portuguese; Russian; Slovak; Slovenian; Spanish; Swedish; Welsh
ALS Cognitive and Behavioral Screen (ALS-CBS)<10 minExecutive functions including attention, concentration, mental tracking and monitoring, verbal fluency
Behavioral changes		YesBrazilian; Spanish; Greek
ALS Brief Cognitive Assessment (ALS-BCA)5 minExecutive functions (working memory, set-shifting), Frontally-mediated language function, Delayed verbal recall, Behavioral changesN/AN/A
Beaumont Behavioral Inventory (BBI)5–10 minFrontal Behavioral symptoms; Executive functions; Language; Psychotic symptomsN/AN/A
Motor Neuron Disease Behavioral Instrument (MiND-B)<10 minBehavioral symptomsN/AN/A
ALS Frontotemporal Dementia Questionnaire (ALS-FTD-Q)5–10 minBehavioral symptoms (it also includes 3 items for memory, concentration and orientation in time)N/AN/A

Research opportunities and future directions

Even though the high incidence of cognitive impairment and its impact on individualized patient care are now universally recognized, the neuropsychological aspects of ALS are seldom considered for patient stratification in clinical trials (228). Several ALS-specific cognitive screening tests have now been validated, but generic tests, such as MOCA and MMSE are still in use in some clinics. While neuropsychological scores are often adjusted for motor-disability and depression, medication-effects, fatigue, and hypoxia are seldom considered when interpreting cognitive performance on various instruments. Despite sporadic reports, the full spectrum of psychiatric manifestations and the precise incidence of psychosis remain to be established in ALS (119, 229, 230). Certain cognitive domains, such as memory and praxis have not been exhaustively characterized in ALS to date. Relatively little is known of the neuropsychological profile of ALS-causing mutation carriers before they develop motor symptoms (231–233). The gaps in our current understanding of extra-motor pathology in ALS shape future study designs. Novel technologies such as online assessments, internet-based data collection, mobile phone apps, and wearable devices are emerging research resources. Irrespective of specific neuropsychological instruments, the early detection, and careful of monitoring of cognitive deficits in ALS is pivotal for optimized patient and caregiver support and tailoring precision management strategies to individual patient needs.

Author contributions

The paper was drafted by FC, EK, and PB and has been reviewed for intellectual content by MR, NK, and IE.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

FC is supported by the State Scholarships Foundation (I.K.Y.; Postdoctoral Support; EP ANADEDBM/ESPA 2014–2020). Peter Bede's group is supported by the Health Research Board (HRB–Ireland; HRB EIA-2017-019), the Andrew Lydon scholarship, the Irish Institute of Clinical Neuroscience IICN–Novartis Ireland Research Grant, the Iris O'Brien Foundation, the Perrigo Clinician-Scientist Research Fellowship, and the Research Motor Neuron (RMN–Ireland) Foundation.

References

1. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. . Amyotrophic lateral sclerosis. Lancet (2011) 377:942–55. 10.1016/S0140-6736(10)61156-7 [Abstract] [CrossRef] [Google Scholar]
2. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. . Ubiquitinated TDP−43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 314:130–3. 10.1126/science.1134108 [Abstract] [CrossRef] [Google Scholar]
3. Gallassi R, Montagna P, Ciardulli C, Lorusso S, Mussuto V, Stracciari A. Cognitive impairment in motor neuron disease. Acta Neurol Scand. (1985) 71:480–4. 10.1111/j.1600-0404.1985.tb03231.x [Abstract] [CrossRef] [Google Scholar]
4. David AS, Gillham RA. Neuropsychological study of motor neuron disease. Psychosomatics (1986) 27:441–5. 10.1016/S0033-3182(86)72673-X [Abstract] [CrossRef] [Google Scholar]
5. Silani V, Ludolph A, Fornai F. The emerging picture of ALS: a multisystem, not only a "motor neuron disease. Arch Ital Biol. (2017) 155:99–109. [Abstract] [Google Scholar]
6. Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain (1981) 104:217–47. 10.1093/brain/104.2.217 [Abstract] [CrossRef] [Google Scholar]
7. Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ. The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry (2016) 87:611–9. 10.1136/jnnp-2015-310734 [Abstract] [CrossRef] [Google Scholar]
8. Beeldman E, Raaphorst J, Klein Twennaar M, Govaarts R, Pijnenburg YAL, de Haan RJ, et al. . The cognitive profile of behavioural variant FTD and its similarities with ALS: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry (2018) 89:995–1002. 10.1136/jnnp-2017-317459 [Abstract] [CrossRef] [Google Scholar]
9. Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. (2013) 12:368–80. 10.1016/S1474-4422(13)70026-7 [Abstract] [CrossRef] [Google Scholar]
10. Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, et al. . Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry (2015) 86:168–73. 10.1136/jnnp-2013-307223 [Abstract] [CrossRef] [Google Scholar]
11. Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, et al. . The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry (2012) 83:102–8. 10.1136/jnnp-2011-300188 [Abstract] [CrossRef] [Google Scholar]
12. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology (2005) 65:586–90. 10.1212/01.wnl.0000172911.39167.b6 [Abstract] [CrossRef] [Google Scholar]
13. Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, et al. . Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort. J Neurol. (2017) 264:2224–31. 10.1007/s00415-017-8619-4 [Abstract] [CrossRef] [Google Scholar]
14. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 72:257–68. 10.1016/j.neuron.2011.09.010 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
15. Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. . ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology (2018) 91:e1370–80. 10.1212/WNL.0000000000006317 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
16. Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. . Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. (2012) 11:232–40. 10.1016/S1474-4422(12)70014-5 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
17. Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, et al. . Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology (2013) 80:1590–7. 10.1212/WNL.0b013e31828f18ac [Abstract] [CrossRef] [Google Scholar]
18. Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, et al. . Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology (2011) 76:1263–9. 10.1212/WNL.0b013e318214359f [Abstract] [CrossRef] [Google Scholar]
19. Olney RK, Murphy J, Forshew D, Garwood E, Miller BL, Langmore S, et al. . The effects of executive and behavioral dysfunction on the course of ALS. Neurology (2005) 65:1774–7. 10.1212/01.wnl.0000188759.87240.8b [Abstract] [CrossRef] [Google Scholar]
20. Merrilees J, Klapper J, Murphy J, Lomen-Hoerth C, Miller BL. Cognitive and behavioral challenges in caring for patients with frontotemporal dementia and amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2010) 11:298–302. 10.3109/17482961003605788 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
21. Abrahams S, Goldstein LH, Lloyd CM, Brooks DJ, Leigh PN. Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: a neuropsychological investigation. J Neurol Sci. (1995) 129(Suppl.):54–5. 10.1016/0022-510X(95)00063-8 [Abstract] [CrossRef] [Google Scholar]
22. Abrahams S, Leigh PN, Kew JJ, Goldstein LH, Lloyd CM, Brooks DJ. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. J Neurol Sci. (1995) 129(Suppl.):44–6. 10.1016/0022-510X(95)00060-F [Abstract] [CrossRef] [Google Scholar]
23. Pinto-Grau M, Hardiman O, Pender N. The study of language in the amyotrophic lateral sclerosis - frontotemporal spectrum disorder: a systematic review of findings and new perspectives. Neuropsychol Rev. (2018) 28:251–68. 10.1007/s11065-018-9375-7 [Abstract] [CrossRef] [Google Scholar]
24. Taylor LJ, Brown RG, Tsermentseli S, Al-Chalabi A, Shaw CE, Ellis CM, et al. . Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry (2013) 84:494–8. 10.1136/jnnp-2012-303526 [Abstract] [CrossRef] [Google Scholar]
25. Christidi F, Karavasilis E, Zalonis I, Ferentinos P, Giavri Z, Wilde EA, et al. . Memory-related white matter tract integrity in amyotrophic lateral sclerosis: an advanced neuroimaging and neuropsychological study. Neurobiol Aging (2017) 49:69–78. 10.1016/j.neurobiolaging.2016.09.014 [Abstract] [CrossRef] [Google Scholar]
26. Machts J, Bittner V, Kasper E, Schuster C, Prudlo J, Abdulla S, et al. Memory deficits in amyotrophic lateral sclerosis are not exclusively caused by executive dysfunction: a comparative neuropsychological study of amnestic mild cognitive impairment. BMC Neurosci. (2014) 15:83 10.1186/1471-2202-15-83 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
27. Abrahams S, Goldstein LH, Al-Chalabi A, Pickering A, Morris RG, Passingham RE, et al. . Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (1997) 62:464–72. 10.1136/jnnp.62.5.464 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
28. Bora E. Meta-analysis of social cognition in amyotrophic lateral sclerosis. Cortex (2017) 88:1–7. 10.1016/j.cortex.2016.11.012 [Abstract] [CrossRef] [Google Scholar]
29. Consonni M, Catricala E, Dalla Bella E, Gessa VC, Lauria G, Cappa SF. Beyond the consensus criteria: multiple cognitive profiles in amyotrophic lateral sclerosis? Cortex (2016) 81:162–7. 10.1016/j.cortex.2016.04.014 [Abstract] [CrossRef] [Google Scholar]
30. Goldstein S. Handbook of Executive Functioning. New York, NY: Springer; (2014). [Google Scholar]
31. Lezak MD. Neuropsychological Assessment. 5th ed. ed Oxford New York, NY: Oxford University Press; (2012) p. 1161. [Google Scholar]
32. Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia (2000) 38:734–47. 10.1016/S0028-3932(99)00146-3 [Abstract] [CrossRef] [Google Scholar]
33. Abrahams S, Goldstein LH, Kew JJ, Brooks DJ, Lloyd CM, Frith CD, et al. . Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain (1996) 119(Pt. 6):2105–20. [Abstract] [Google Scholar]
34. Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology (2005) 64:1222–6. 10.1212/01.WNL.0000156519.41681.27 [Abstract] [CrossRef] [Google Scholar]
35. Frank B, Haas J, Heinze HJ, Stark E, Munte TF. Relation of neuropsychological and magnetic resonance findings in amyotrophic lateral sclerosis: evidence for subgroups. Clin Neurol Neurosurg. (1997) 99:79–86. 10.1016/S0303-8467(97)80001-7 [Abstract] [CrossRef] [Google Scholar]
36. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology (2003) 60:1094–7. 10.1212/01.WNL.0000055861.95202.8D [Abstract] [CrossRef] [Google Scholar]
37. Hanagasi HA, Gurvit IH, Ermutlu N, Kaptanoglu G, Karamursel S, Idrisoglu HA, et al. . Cognitive impairment in amyotrophic lateral sclerosis: evidence from neuropsychological investigation and event-related potentials. Brain Res Cogn Brain Res. (2002) 14:234–44. 10.1016/S0926-6410(02)00110-6 [Abstract] [CrossRef] [Google Scholar]
38. Kew JJ, Goldstein LH, Leigh PN, Abrahams S, Cosgrave N, Passingham RE, et al. . The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain (1993) 116(Pt 6):1399–423. [Abstract] [Google Scholar]
39. Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T, et al. . Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand. (1992) 85:81–9. 10.1111/j.1600-0404.1992.tb04003.x [Abstract] [CrossRef] [Google Scholar]
40. Pinkhardt EH, Jurgens R, Becker W, Molle M, Born J, Ludolph AC, et al. . Signs of impaired selective attention in patients with amyotrophic lateral sclerosis. J Neurol. (2008) 255:532–8. 10.1007/s00415-008-0734-9 [Abstract] [CrossRef] [Google Scholar]
41. Massman PJ, Sims J, Cooke N, Haverkamp LJ, Appel V, Appel SH. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (1996) 61:450–5. 10.1136/jnnp.61.5.450 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
42. Witgert M, Salamone AR, Strutt AM, Jawaid A, Massman PJ, Bradshaw M, et al. . Frontal-lobe mediated behavioral dysfunction in amyotrophic lateral sclerosis. Eur J Neurol. (2010) 17:103–10. 10.1111/j.1468-1331.2009.02801.x [Abstract] [CrossRef] [Google Scholar]
43. Rakowicz WP, Hodges JR. Dementia and aphasia in motor neuron disease: an underrecognised association? J Neurol Neurosurg Psychiatry (1998) 65:881–9. 10.1136/jnnp.65.6.881 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
44. Stukovnik V, Zidar J, Podnar S, Repovs G. Amyotrophic lateral sclerosis patients show executive impairments on standard neuropsychological measures and an ecologically valid motor-free test of executive functions. J Clin Exp Neuropsychol. (2010) 32:1095–109. 10.1080/13803391003749236 [Abstract] [CrossRef] [Google Scholar]
45. Wicks P, Abrahams S, Papps B, Al-Chalabi A, Shaw CE, Leigh PN, et al. . SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J Neurol. (2009) 256:234–41. 10.1007/s00415-009-0078-0 [Abstract] [CrossRef] [Google Scholar]
46. Abrahams S, Goldstein LH, Simmons A, Brammer M, Williams SC, Giampietro V, et al. . Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Brain (2004) 127(Pt 7):1507–17. 10.1093/brain/awh170 [Abstract] [CrossRef] [Google Scholar]
47. Hartikainen P, Helkala EL, Soininen H, Riekkinen P, Sr. Cognitive and memory deficits in untreated Parkinson's disease and amyotrophic lateral sclerosis patients: a comparative study. J Neural Transm Park Dis Dement Sect. (1993) 6:127–37. 10.1007/BF02261006 [Abstract] [CrossRef] [Google Scholar]
48. Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:9–14. 10.3109/21678421.2013.805784 [Abstract] [CrossRef] [Google Scholar]
49. Evdokimidis I, Constantinidis TS, Gourtzelidis P, Smyrnis N, Zalonis I, Zis PV, et al. . Frontal lobe dysfunction in amyotrophic lateral sclerosis. J Neurol Sci. (2002) 195:25–33. 10.1016/S0022-510X(01)00683-9 [Abstract] [CrossRef] [Google Scholar]
50. Libon DJ, McMillan C, Avants B, Boller A, Morgan B, Burkholder L, et al. . Deficits in concept formation in amyotrophic lateral sclerosis. Neuropsychology (2012) 26:422–9. 10.1037/a0028668 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
51. Moretti R, Torre P, Antonello RM, Carraro N, Cazzato G, Bava A. Complex cognitive disruption in motor neuron disease. Dement Geriatr Cogn Disord. (2002) 14:141–50. 10.1159/000063600 [Abstract] [CrossRef] [Google Scholar]
52. Schreiber H, Gaigalat T, Wiedemuth-Catrinescu U, Graf M, Uttner I, Muche R, et al. . Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients. J Neurol. (2005) 252:772–81. 10.1007/s00415-005-0739-6 [Abstract] [CrossRef] [Google Scholar]
53. Zalonis I, Christidi F, Paraskevas G, Zabelis T, Evdokimidis I, Kararizou E. Can executive cognitive measures differentiate between patients with spinal- and bulbar-onset amyotrophic lateral sclerosis? Arch Clin Neuropsychol. (2012) 27:348–54. 10.1093/arclin/acs031 [Abstract] [CrossRef] [Google Scholar]
54. Hammer A, Vielhaber S, Rodriguez-Fornells A, Mohammadi B, Munte TF. A neurophysiological analysis of working memory in amyotrophic lateral sclerosis. Brain Res. (2011) 1421:90–9. 10.1016/j.brainres.2011.09.010 [Abstract] [CrossRef] [Google Scholar]
55. Kilani M, Micallef J, Soubrouillard C, Rey-Lardiller D, Demattei C, Dib M, et al. . A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. (2004) 5:46–54. 10.1080/14660820310017560 [Abstract] [CrossRef] [Google Scholar]
56. Lule D, Diekmann V, Anders S, Kassubek J, Kubler A, Ludolph AC, et al. . Brain responses to emotional stimuli in patients with amyotrophic lateral sclerosis (ALS). J Neurol. (2007) 254:519–27. 10.1007/s00415-006-0409-3 [Abstract] [CrossRef] [Google Scholar]
57. Sterling LE, Jawaid A, Salamone AR, Murthy SB, Mosnik DM, McDowell E, et al. . Association between dysarthria and cognitive impairment in ALS: a prospective study. Amyotroph Lateral Scler. (2010) 11:46–51. 10.3109/17482960903207997 [Abstract] [CrossRef] [Google Scholar]
58. Jelsone-Swain L, Persad C, Votruba KL, Weisenbach SL, Johnson T, Gruis KL, et al. . The relationship between depressive symptoms, disease state, and cognition in amyotrophic lateral sclerosis. Front Psychol. (2012) 3:542. 10.3389/fpsyg.2012.00542 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
59. Mioshi E, Lillo P, Yew B, Hsieh S, Savage S, Hodges JR, et al. . Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology (2013) 80:1117–23. 10.1212/WNL.0b013e31828869da [Abstract] [CrossRef] [Google Scholar]
60. Christidi F, Zalonis I, Smyrnis N, Evdokimidis I. Selective attention and the three-process memory model for the interpretation of verbal free recall in amyotrophic lateral sclerosis. J Int Neuropsychol Soc. (2012) 18:809–18. 10.1017/S1355617712000562 [Abstract] [CrossRef] [Google Scholar]
61. Lillo P, Mioshi E, Burrell JR, Kiernan MC, Hodges JR, Hornberger M. Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS ONE (2012) 7: e43993. 10.1371/journal.pone.0043993 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
62. Newsom-Davis IC, Lyall RA, Leigh PN, Moxham J, Goldstein LH. The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study. J Neurol Neurosurg Psychiatry (2001) 71:482–7. 10.1136/jnnp.71.4.482 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
63. Meier SL, Charleston AJ, Tippett LJ. Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic lateral sclerosis. Brain (2010) 133:3444–57. 10.1093/brain/awq254 [Abstract] [CrossRef] [Google Scholar]
64. Christidi F, Karavasilis E, Velonakis G, Ferentinos P, Rentzos M, Kelekis N, et al. . The clinical and radiological spectrum of hippocampal pathology in amyotrophic lateral sclerosis. Front Neurol. (2018) 9:523. 10.3389/fneur.2018.00523 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
65. Hsieh S, Irish M, Foxe D, Caga J, Devenney E, Ahmed R, et al. . My memories are important to me: changes in autobiographical memory in amyotrophic lateral sclerosis. Neuropsychology (2016) 30:920–30. 10.1037/neu0000291 [Abstract] [CrossRef] [Google Scholar]
66. Hervieu-Begue M, Rouaud O, Graule Petot A, Catteau A, Giroud M. Semantic memory assessment in 15 patients with amyotrophic lateral sclerosis. Revue Neurol. (2016) 172:307–12. 10.1016/j.neurol.2015.10.009 [Abstract] [CrossRef] [Google Scholar]
67. Iwasaki Y, Kinoshita M, Ikeda K, Takamiya K, Shiojima T. Cognitive impairment in amyotrophic lateral sclerosis and its relation to motor disabilities. Acta Neurol Scand. (1990) 81:141–3. 10.1111/j.1600-0404.1990.tb00950.x [Abstract] [CrossRef] [Google Scholar]
68. Mantovan MC, Baggio L, Dalla Barba G, Smith P, Pegoraro E, Soraru G, et al. . Memory deficits and retrieval processes in ALS. Eur J Neurol. (2003) 10:221–7. 10.1046/j.1468-1331.2003.00607.x [Abstract] [CrossRef] [Google Scholar]
69. Abe K, Fujimura H, Toyooka K, Sakoda S, Yorifuji S, Yanagihara T. Cognitive function in amyotrophic lateral sclerosis. J Neurol Sci. (1997) 148:95–100. 10.1016/S0022-510X(96)05338-5 [Abstract] [CrossRef] [Google Scholar]
70. Raaphorst J, van Tol MJ, de Visser M, van der Kooi AJ, Majoie CB, van den Berg LH, et al. . Prose memory impairment in amyotrophic lateral sclerosis patients is related to hippocampus volume. Eur J Neurol. (2015) 22:547–54. 10.1111/ene.12615 [Abstract] [CrossRef] [Google Scholar]
71. Bede P, Omer T, Finegan E, Chipika RH, Iyer PM, Doherty MA, et al. . Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. Brain Imag Behav. (2018). 10.1007/s11682-018-9837-9. [Epub ahead of print]. [Abstract] [CrossRef] [Google Scholar]
72. Omer T, Finegan E, Hutchinson S, Doherty M, Vajda A, McLaughlin RL, et al. . Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:611–23. 10.1080/21678421.2017.1332077 [Abstract] [CrossRef] [Google Scholar]
73. Ash S, Olm C, McMillan CT, Boller A, Irwin DJ, McCluskey L, et al. . Deficits in sentence expression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:31–9. 10.3109/21678421.2014.974617 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
74. Tsermentseli S, Leigh PN, Taylor LJ, Radunovic A, Catani M, Goldstein LH. Syntactic processing as a marker for cognitive impairment in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 17:69–76. 10.3109/21678421.2015.1071397 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
75. Bak TH, O'Donovan DG, Xuereb JH, Boniface S, Hodges JR. Selective impairment of verb processing associated with pathological changes in Brodmann areas 44 and 45 in the motor neurone disease-dementia-aphasia syndrome. Brain (2001) 124(Pt 1):103–20. 10.1093/brain/124.1.103 [Abstract] [CrossRef] [Google Scholar]
76. Papeo L, Cecchetto C, Mazzon G, Granello G, Cattaruzza T, Verriello L, et al. . The processing of actions and action-words in amyotrophic lateral sclerosis patients. Cortex (2015) 64:136–47. 10.1016/j.cortex.2014.10.007 [Abstract] [CrossRef] [Google Scholar]
77. Grossman M, Anderson C, Khan A, Avants B, Elman L, McCluskey L. Impaired action knowledge in amyotrophic lateral sclerosis. Neurology (2008) 71:1396–401. 10.1212/01.wnl.0000319701.50168.8c [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
78. York C, Olm C, Boller A, McCluskey L, Elman L, Haley J, et al. . Action verb comprehension in amyotrophic lateral sclerosis and Parkinson's disease. J Neurol. (2014) 261:1073–9. 10.1007/s00415-014-7314-y [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
79. Bak TH, Chandran S. What wires together dies together: verbs, actions and neurodegeneration in motor neuron disease. Cortex (2012) 48:936–44. 10.1016/j.cortex.2011.07.008 [Abstract] [CrossRef] [Google Scholar]
80. Roberts-South A, Findlater K, Strong MJ, Orange JB. Longitudinal changes in discourse production in amyotrophic lateral sclerosis. Semin Speech Language (2012) 33:79–94. 10.1055/s-0031-1301165 [Abstract] [CrossRef] [Google Scholar]
81. Bambini V, Arcara G, Martinelli I, Bernini S, Alvisi E, Moro A, et al. Communication and pragmatic breakdowns in amyotrophic lateral sclerosis patients. Brain Language (2016) 153–154:1–12. 10.1016/j.bandl.2015.12.002 [Abstract] [CrossRef] [Google Scholar]
82. Yunusova Y, Graham NL, Shellikeri S, Phuong K, Kulkarni M, Rochon E, et al. . Profiling speech and pausing in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). PLoS ONE (2016) 11:e0147573. 10.1371/journal.pone.0147573 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
83. Kamminga J, Leslie FVC, Hsieh S, Caga J, Mioshi E, Hornberger M, et al. . Syntactic comprehension deficits across the FTD-ALS continuum. Neurobiol Aging (2016) 41:11–8. 10.1016/j.neurobiolaging.2016.02.002 [Abstract] [CrossRef] [Google Scholar]
84. Yoshizawa K, Yasuda N, Fukuda M, Yukimoto Y, Ogino M, Hata W, et al. . Syntactic comprehension in patients with amyotrophic lateral sclerosis. Behav Neurol. (2014) 2014:230578. 10.1155/2014/230578 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
85. Strong MJ, Grace GM, Orange JB, Leeper HA, Menon RS, Aere C. A prospective study of cognitive impairment in ALS. Neurology (1999) 53:1665–70. 10.1212/WNL.53.8.1665 [Abstract] [CrossRef] [Google Scholar]
86. Bede P, Iyer PM, Schuster C, Elamin M, McLaughlin RL, Kenna K, et al. . The selective anatomical vulnerability of ALS: 'disease-defining' and 'disease-defying' brain regions. Amyotroph Lateral Scler Frontotemporal Degener. (2016) 17:561–70. 10.3109/21678421.2016.1173702 [Abstract] [CrossRef] [Google Scholar]
87. Geser F, Brandmeir NJ, Kwong LK, Martinez-Lage M, Elman L, McCluskey L, et al. . Evidence of multisystem disorder in whole-brain map of pathological TDP−43 in amyotrophic lateral sclerosis. Arch Neurol. (2008) 65:636–41. 10.1001/archneur.65.5.636 [Abstract] [CrossRef] [Google Scholar]
88. Lobo PP, Pinto S, Rocha L, Reimao S, de Carvalho M. Orofacial apraxia in motor neuron disease. Case Rep Neurol. (2013) 5:47–51. 10.1159/000349895 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
89. Duffy JR, Peach RK, Strand EA. Progressive apraxia of speech as a sign of motor neuron disease. Am J Speech Language Pathol. (2007) 16:198–208. 10.1044/1058-0360(2007/025) [Abstract] [CrossRef] [Google Scholar]
90. Pinto S, Pinto A, Atalaia A, Peralta R, de Carvalho M. Respiratory apraxia in amyotrophic lateral sclerosis. Amyotr Lateral Scler. (2007) 8:180–4. 10.1080/17482960701249340 [Abstract] [CrossRef] [Google Scholar]
91. Adolphs R. The social brain: neural basis of social knowledge. Ann Rev Psychol. (2009) 60:693–716. 10.1146/annurev.psych.60.110707.163514 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
92. Christidi F, Migliaccio R, Santamaria-Garcia H, Santangelo G, Trojsi F. Social cognition dysfunctions in neurodegenerative diseases: neuroanatomical correlates and clinical implications. Behav Neurol. (2018) 2018:1849794. 10.1155/2018/1849794 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
93. Carluer L, Mondou A, Buhour MS, Laisney M, Pelerin A, Eustache F, et al. . Neural substrate of cognitive theory of mind impairment in amyotrophic lateral sclerosis. Cortex (2015) 65:19–30. 10.1016/j.cortex.2014.12.010 [Abstract] [CrossRef] [Google Scholar]
94. Cavallo M, Adenzato M, Macpherson SE, Karwig G, Enrici I, Abrahams S. Evidence of social understanding impairment in patients with amyotrophic lateral sclerosis. PLoS ONE (2011) 6:e25948. 10.1371/journal.pone.0025948 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
95. Cerami C, Dodich A, Canessa N, Crespi C, Iannaccone S, Corbo M, et al. . Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:21–9. 10.3109/21678421.2013.785568 [Abstract] [CrossRef] [Google Scholar]
96. Girardi A, MacPherson SE, Abrahams S. Deficits in emotional and social cognition in amyotrophic lateral sclerosis. Neuropsychology (2011) 25:53–65. 10.1037/a0020357 [Abstract] [CrossRef] [Google Scholar]
97. Watermeyer TJ, Brown RG, Sidle KC, Oliver DJ, Allen C, Karlsson J, et al. . Executive dysfunction predicts social cognition impairment in amyotrophic lateral sclerosis. J Neurol. (2015) 262:1681–90. 10.1007/s00415-015-7761-0 [Abstract] [CrossRef] [Google Scholar]
98. Staios M, Fisher F, Lindell AK, Ong B, Howe J, Reardon K. Exploring sarcasm detection in amyotrophic lateral sclerosis using ecologically valid measures. Front Hum Neurosci. (2013) 7:178. 10.3389/fnhum.2013.00178 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
99. Trojsi F, Siciliano M, Russo A, Passaniti C, Femiano C, Ferrantino T, et al. . Theory of mind and its neuropsychological and quality of life correlates in the early stages of amyotrophic lateral sclerosis. Front Psychol. (2016) 7:1934. 10.3389/fpsyg.2016.01934 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
100. Savage SA, Lillo P, Kumfor F, Kiernan MC, Piguet O, Hodges JR. Emotion processing deficits distinguish pure amyotrophic lateral sclerosis from frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:39–46. 10.3109/21678421.2013.809763 [Abstract] [CrossRef] [Google Scholar]
101. Palmieri A, Naccarato M, Abrahams S, Bonato M, D'Ascenzo C, Balestreri S, et al. . Right hemisphere dysfunction and emotional processing in ALS: an fMRI study. J Neurol. (2010) 257:1970–8. 10.1007/s00415-010-5640-2 [Abstract] [CrossRef] [Google Scholar]
102. Crespi C, Cerami C, Dodich A, Canessa N, Arpone M, Iannaccone S, et al. . Microstructural white matter correlates of emotion recognition impairment in Amyotrophic Lateral Sclerosis. Cortex (2014) 53:1–8. 10.1016/j.cortex.2014.01.002 [Abstract] [CrossRef] [Google Scholar]
103. Andrews SC, Staios M, Howe J, Reardon K, Fisher F. Multimodal emotion processing deficits are present in amyotrophic lateral sclerosis. Neuropsychology (2017) 31:304–10. 10.1037/neu0000323 [Abstract] [CrossRef] [Google Scholar]
104. Gibbons ZC, Snowden JS, Thompson JC, Happe F, Richardson A, Neary D. Inferring thought and action in motor neurone disease. Neuropsychologia (2007) 45:1196–207. 10.1016/j.neuropsychologia.2006.10.008 [Abstract] [CrossRef] [Google Scholar]
105. Burke T, Elamin M, Bede P, Pinto-Grau M, Lonergan K, Hardiman O, et al. . Discordant performance on the 'Reading the Mind in the Eyes' Test, based on disease onset in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2016) 17:467–72. 10.1080/21678421.2016.1177088 [Abstract] [CrossRef] [Google Scholar]
106. Elamin M, Pinto-Grau M, Burke T, Bede P, Rooney J, O'Sullivan M, et al. . Identifying behavioural changes in ALS: validation of the Beaumont Behavioural Inventory (BBI). Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:68–73. 10.1080/21678421.2016.1248976. [Abstract] [CrossRef] [Google Scholar]
107. Raaphorst J, Beeldman E, De Visser M, De Haan RJ, Schmand B. A systematic review of behavioural changes in motor neuron disease. Amyotroph Lateral Scler. (2012) 13:493–501. 10.3109/17482968.2012.656652 [Abstract] [CrossRef] [Google Scholar]
108. Grossman AB, Woolley-Levine S, Bradley WG, Miller RG. Detecting neurobehavioral changes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2007) 8:56–61. 10.1080/17482960601044106 [Abstract] [CrossRef] [Google Scholar]
109. Chio A, Vignola A, Mastro E, Giudici AD, Iazzolino B, Calvo A, et al. . Neurobehavioral symptoms in ALS are negatively related to caregivers' burden and quality of life. Eur J Neurol. (2010) 17:1298–303. 10.1111/j.1468-1331.2010.03016.x [Abstract] [CrossRef] [Google Scholar]
110. Grace J, Mallow P.F. Frontal Systems Behavior Scale. Lutz, FL: Psychological Assessment Resources; (2001). [Google Scholar]
111. Kertesz A, Davidson W, Fox H. Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci. (1997) 24:29–36. [Abstract] [Google Scholar]
112. Radakovic R, Abrahams S. Developing a new apathy measurement scale: dimensional apathy scale. Psychiatry Res. (2014) 219:658–63. 10.1016/j.psychres.2014.06.010 [Abstract] [CrossRef] [Google Scholar]
113. Radakovic R, Stephenson L, Colville S, Swingler R, Chandran S, Abrahams S. Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale. J Neurol Neurosurg Psychiatry (2016) 87:663–9. 10.1136/jnnp-2015-310772 [Abstract] [CrossRef] [Google Scholar]
114. Terada T, Obi T, Yoshizumi M, Murai T, Miyajima H, Mizoguchi K. Frontal lobe-mediated behavioral changes in amyotrophic lateral sclerosis: are they independent of physical disabilities? J Neurol Sci. (2011) 309:136–40. 10.1016/j.jns.2011.06.049 [Abstract] [CrossRef] [Google Scholar]
115. Turner MR, Talbot K. Sweet food preference in amyotrophic lateral sclerosis. Pract Neurol. (2017) 17:128–9. 10.1136/practneurol-2016-001554 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
116. Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AM, et al. . Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain (2012) 135(Pt 3):693–708. 10.1093/brain/awr355 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
117. Kertesz A, Ang LC, Jesso S, MacKinley J, Baker M, Brown P, et al. . Psychosis and hallucinations in frontotemporal dementia with the C9ORF72 mutation: a detailed clinical cohort. Cogn Behav Neurol. (2013) 26:146–54. 10.1097/WNN.0000000000000008 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
118. Nitrini R, Rosemberg S. Psychotic symptoms in dementia associated with motor neuron disease: a pathophysiological hypothesis. J Neuropsychiatry Clin Neurosci. (1998) 10:456–8. 10.1176/jnp.10.4.456 [Abstract] [CrossRef] [Google Scholar]
119. Lillo P, Garcin B, Hornberger M, Bak TH, Hodges JR. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol. (2010) 67:826–30. 10.1001/archneurol.2010.146 [Abstract] [CrossRef] [Google Scholar]
120. Noh SM, Chung SJ, Kim KK, Kang DW, Lim YM, Kwon SU, et al. . Emotional disturbance in CADASIL: its impact on quality of life and caregiver burden. Cerebrovasc Dis. (2014) 37:188–94. 10.1159/000357798 [Abstract] [CrossRef] [Google Scholar]
121. Lauterbach EC, Cummings JL, Kuppuswamy PS. Toward a more precise, clinically–informed pathophysiology of pathological laughing and crying. Neurosci Biobehav Rev. (2013) 37:1893–916. 10.1016/j.neubiorev.2013.03.002 [Abstract] [CrossRef] [Google Scholar]
122. Bede P, Finegan E. Revisiting the pathoanatomy of pseudobulbar affect: mechanisms beyond corticobulbar dysfunction. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:4–6. 10.1080/21678421.2017.1392578 [Abstract] [CrossRef] [Google Scholar]
123. Brooks BR, Crumpacker D, Fellus J, Kantor D, Kaye RE. PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions. PLoS ONE (2013) 8:e72232. 10.1371/journal.pone.0072232 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
124. Palmieri A, Abrahams S, Soraru G, Mattiuzzi L, D'Ascenzo C, Pegoraro E, et al. . Emotional Lability in MND: Relationship to cognition and psychopathology and impact on caregivers. J Neurol Sci. (2009) 278:16–20. 10.1016/j.jns.2008.10.025 [Abstract] [CrossRef] [Google Scholar]
125. McCullagh S, Moore M, Gawel M, Feinstein A. Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction. J Neurol Sci. (1999) 169:43–8. 10.1016/S0022-510X(99)00214-2 [Abstract] [CrossRef] [Google Scholar]
126. Olney NT, Goodkind MS, Lomen-Hoerth C, Whalen PK, Williamson CA, Holley DE, et al. . Behaviour, physiology and experience of pathological laughing and crying in amyotrophic lateral sclerosis. Brain (2011) 134(Pt 12):3458–69. 10.1093/brain/awr297 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
127. Floeter MK, Katipally R, Kim MP, Schanz O, Stephen M, Danielian L, et al. . Impaired corticopontocerebellar tracts underlie pseudobulbar affect in motor neuron disorders. Neurology (2014) 83:620–7. 10.1212/WNL.0000000000000693 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
128. Christidi F, Karavasilis E, Ferentinos P, Xirou S, Velonakis G, Rentzos M, et al. . Investigating the neuroanatomical substrate of pathological laughing and crying in amyotrophic lateral sclerosis with multimodal neuroimaging techniques. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19(1–2):12–20. 10.1080/21678421.2017.1386689 [Abstract] [CrossRef] [Google Scholar]
129. Verstraete E, Turner MR, Grosskreutz J, Filippi M, Benatar M. Mind the gap: The mismatch between clinical and imaging metrics in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:524–9. 10.3109/21678421.2015.1051989 [Abstract] [CrossRef] [Google Scholar]
130. Bede P, Querin G, Pradat PF. The changing landscape of motor neuron disease imaging: the transition from descriptive studies to precision clinical tools. Curr Opin Neurol. (2018) 31:431–8. 10.1097/WCO.0000000000000569 [Abstract] [CrossRef] [Google Scholar]
131. Shen D, Cui L, Fang J, Cui B, Li D, Tai H. Voxel-wise meta-analysis of gray matter changes in amyotrophic lateral sclerosis. Front Aging Neurosci. (2016) 8:64. 10.3389/fnagi.2016.00064 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
132. Bede P, Hardiman O. Lessons of ALS imaging: Pitfalls and future directions - A critical review. NeuroImage Clin. (2014) 4:436–43. 10.1016/j.nicl.2014.02.011 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
133. Bede P, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A, et al. . Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology (2013) 81:2107–15. 10.1212/01.wnl.0000437313.80913.2c [Abstract] [CrossRef] [Google Scholar]
134. Bede P, Bokde A, Elamin M, Byrne S, McLaughlin RL, Jordan N, et al. . Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry (2013) 84:766–73. 10.1136/jnnp-2012-302674 [Abstract] [CrossRef] [Google Scholar]
135. Bede P, Bokde AL, Byrne S, Elamin M, McLaughlin RL, Kenna K, et al. . Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology (2013) 81:361–9. 10.1212/WNL.0b013e31829c5eee [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
136. Westeneng HJ, Verstraete E, Walhout R, Schmidt R, Hendrikse J, Veldink JH, et al. . Subcortical structures in amyotrophic lateral sclerosis. Neurobiol Aging (2015) 36:1075–82. 10.1016/j.neurobiolaging.2014.09.002 [Abstract] [CrossRef] [Google Scholar]
137. Pinkhardt EH, van Elst LT, Ludolph AC, Kassubek J. Amygdala size in amyotrophic lateral sclerosis without dementia: an in vivo study using MRI volumetry. BMC Neurol. (2006) 6:48. 10.1186/1471-2377-6-48 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
138. Machts J, Loewe K, Kaufmann J, Jakubiczka S, Abdulla S, Petri S, et al. . Basal ganglia pathology in ALS is associated with neuropsychological deficits. Neurology (2015) 85:1301–9. 10.1212/WNL.0000000000002017 [Abstract] [CrossRef] [Google Scholar]
139. Thivard L, Pradat PF, Lehericy S, Lacomblez L, Dormont D, Chiras J, et al. . Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: relationships with motor disability. J Neurol Neurosurg Psychiatry (2007) 78:889–92. 10.1136/jnnp.2006.101758 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
140. Chang JL, Lomen-Hoerth C, Murphy J, Henry RG, Kramer JH, Miller BL, et al. . A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology (2005) 65:75–80. 10.1212/01.wnl.0000167602.38643.29 [Abstract] [CrossRef] [Google Scholar]
141. Schuster C, Kasper E, Machts J, Bittner D, Kaufmann J, Benecke R, et al. . Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol. (2013) 260:2856–64. 10.1007/s00415-013-7083-z [Abstract] [CrossRef] [Google Scholar]
142. Bede P, Hardiman O. Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration. Amyotroph Lateral Scler Frontotemporal Degener. (2018) 19:232–41. 10.1080/21678421.2017.1407795 [Abstract] [CrossRef] [Google Scholar]
143. Agosta F, Valsasina P, Riva N, Copetti M, Messina MJ, Prelle A, et al. . The cortical signature of amyotrophic lateral sclerosis. PLoS ONE (2012) 7:e42816. 10.1371/journal.pone.0042816 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
144. Mezzapesa DM, Ceccarelli A, Dicuonzo F, Carella A, De Caro MF, Lopez M, et al. . Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol. (2007) 28:255–9. [Europe PMC free article] [Abstract] [Google Scholar]
145. Mezzapesa DM, D'Errico E, Tortelli R, Distaso E, Cortese R, Tursi M, et al. . Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis. PLoS ONE (2013) 8:e80748. 10.1371/journal.pone.0080748 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
146. Christidi F, Karavasilis E, Riederer F, Zalonis I, Ferentinos P, Velonakis G, et al. . Gray matter and white matter changes in non-demented amyotrophic lateral sclerosis patients with or without cognitive impairment: a combined voxel-based morphometry and tract-based spatial statistics whole-brain analysis. Brain Imaging Behav. (2018) 12:547–63. 10.1007/s11682-017-9722-y [Abstract] [CrossRef] [Google Scholar]
147. Alruwaili AR, Pannek K, Coulthard A, Henderson R, Kurniawan ND, McCombe P. A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis. J Neuroradiol. (2018) 45:41–8. 10.1016/j.neurad.2017.03.007 [Abstract] [CrossRef] [Google Scholar]
148. Murphy JM, Henry RG, Langmore S, Kramer JH, Miller BL, Lomen-Hoerth C. Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol. (2007) 64:530–4. 10.1001/archneur.64.4.530 [Abstract] [CrossRef] [Google Scholar]
149. Agosta F, Ferraro PM, Riva N, Spinelli EG, Chio A, Canu E, et al. . Structural brain correlates of cognitive and behavioral impairment in MND. Hum Brain Map. (2016) 37:1614–26. 10.1002/hbm.23124 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
150. Masuda M, Senda J, Watanabe H, Epifanio B, Tanaka Y, Imai K, et al. . Involvement of the caudate nucleus head and its networks in sporadic amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotroph Lateral Scler Frontotemporal Degener. (2016) 17:571–9. 10.1080/21678421.2016.1211151 [Abstract] [CrossRef] [Google Scholar]
151. Zhang F, Chen G, He M, Dai J, Shang H, Gong Q, et al. . Altered white matter microarchitecture in amyotrophic lateral sclerosis: A voxel-based meta-analysis of diffusion tensor imaging. NeuroImage Clin. (2018) 19:122–9. 10.1016/j.nicl.2018.04.005 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
152. Foerster BR, Dwamena BA, Petrou M, Carlos RC, Callaghan BC, Churchill CL, et al. . Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review and individual patient data meta-analysis. Acad Radiol. (2013) 20:1099–106. 10.1016/j.acra.2013.03.017 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
153. Abe O, Yamada H, Masutani Y, Aoki S, Kunimatsu A, Yamasue H, et al. . Amyotrophic lateral sclerosis: diffusion tensor tractography and voxel-based analysis. NMR Biomed. (2004) 17:411–6. 10.1002/nbm.907 [Abstract] [CrossRef] [Google Scholar]
154. Agosta F, Pagani E, Rocca MA, Caputo D, Perini M, Salvi F, et al. . Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability. Hum Brain Map. (2007) 28:1430–8. 10.1002/hbm.20364 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
155. Ciccarelli O, Behrens TE, Johansen-Berg H, Talbot K, Orrell RW, Howard RS, et al. . Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics. Hum Brain Map. (2009) 30:615–24. 10.1002/hbm.20527 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
156. Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology (2010) 75:1645–52. 10.1212/WNL.0b013e3181fb84d1 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
157. Keil C, Prell T, Peschel T, Hartung V, Dengler R, Grosskreutz J. Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neurosci. (2012) 13:141. 10.1186/1471-2202-13-141 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
158. Rosskopf J, Muller HP, Dreyhaupt J, Gorges M, Ludolph AC, Kassubek J. Ex post facto assessment of diffusion tensor imaging metrics from different MRI protocols: preparing for multicentre studies in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:92–101. 10.3109/21678421.2014.977297 [Abstract] [CrossRef] [Google Scholar]
159. Sach M, Winkler G, Glauche V, Liepert J, Heimbach B, Koch MA, et al. . Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain (2004) 127(Pt 2):340–50. 10.1093/brain/awh041 [Abstract] [CrossRef] [Google Scholar]
160. Sage CA, Van Hecke W, Peeters R, Sijbers J, Robberecht W, Parizel P, et al. . Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis: revisited. Hum Brain Map. (2009) 30:3657–75. 10.1002/hbm.20794 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
161. Sato K, Aoki S, Iwata NK, Masutani Y, Watadani T, Nakata Y, et al. . Diffusion tensor tract-specific analysis of the uncinate fasciculus in patients with amyotrophic lateral sclerosis. Neuroradiology (2010) 52:729–33. 10.1007/s00234-010-0653-1 [Abstract] [CrossRef] [Google Scholar]
162. Prell T, Peschel T, Hartung V, Kaufmann J, Klauschies R, Bodammer N, et al. . Diffusion tensor imaging patterns differ in bulbar and limb onset amyotrophic lateral sclerosis. Clin Neurol Neurosurg. (2013) 115:1281–7. 10.1016/j.clineuro.2012.11.031 [Abstract] [CrossRef] [Google Scholar]
163. Sarica A, Cerasa A, Vasta R, Perrotta P, Valentino P, Mangone G, et al. . Tractography in amyotrophic lateral sclerosis using a novel probabilistic tool: a study with tract-based reconstruction compared to voxel-based approach. J Neurosci Methods (2014) 224:79–87. 10.1016/j.jneumeth.2013.12.014 [Abstract] [CrossRef] [Google Scholar]
164. Bede P, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A, et al. . Patterns of cerebral and cerebellar white matter degeneration in ALS. J Neurol Neurosur Psychiatry (2015) 86:468–70. 10.1136/jnnp-2014-308172 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
165. Foerster BR, Carlos RC, Dwamena BA, Callaghan BC, Petrou M, Edden RA, et al. . Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis. Ann Clin Transl Neurol. (2014) 1:107–14. 10.1002/acn3.30 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
166. Sivak S, Bittsansky M, Kurca E, Turcanova-Koprusakova M, Grofik M, Nosal V, et al. . Proton magnetic resonance spectroscopy in patients with early stages of amyotrophic lateral sclerosis. Neuroradiology (2010) 52:1079–85. 10.1007/s00234-010-0685-6 [Abstract] [CrossRef] [Google Scholar]
167. Pyra T, Hui B, Hanstock C, Concha L, Wong JC, Beaulieu C, et al. . Combined structural and neurochemical evaluation of the corticospinal tract in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2010) 11:157–65. 10.3109/17482960902756473 [Abstract] [CrossRef] [Google Scholar]
168. Verma G, Woo JH, Chawla S, Wang S, Sheriff S, Elman LB, et al. . Whole-brain analysis of amyotrophic lateral sclerosis by using echo-planar spectroscopic imaging. Radiology (2013) 267:851–7. 10.1148/radiol.13121148 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
169. Usman U, Choi C, Camicioli R, Seres P, Lynch M, Sekhon R, et al. . Mesial prefrontal cortex degeneration in amyotrophic lateral sclerosis: a high-field proton MR spectroscopy study. AJNR Am J Neuroradiol. (2011) 32:1677–80. 10.3174/ajnr.A2590 [Abstract] [CrossRef] [Google Scholar]
170. Cistaro A, Cuccurullo V, Quartuccio N, Pagani M, Valentini MC, Mansi L. Role of PET and SPECT in the study of amyotrophic lateral sclerosis. BioMed Res Int. (2014) 2014:237437. 10.1155/2014/237437 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
171. Pagani M, Chio A, Valentini MC, Oberg J, Nobili F, Calvo A, et al. . Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology (2014) 83:1067–74. 10.1212/WNL.0000000000000792 [Abstract] [CrossRef] [Google Scholar]
172. Renard D, Collombier L, Castelnovo G, Fourcade G, Kotzki PO, LaBauge P. Brain FDG-PET changes in ALS and ALS-FTD. Acta Neurologica Belgica. (2011) 111:306–9. [Abstract] [Google Scholar]
173. Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, et al. . Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. (2014) 71:553–61. 10.1001/jamaneurol.2014.62 [Abstract] [CrossRef] [Google Scholar]
174. Cistaro A, Valentini MC, Chio A, Nobili F, Calvo A, Moglia C, et al. . Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nuclear Med Mol Imag. (2012) 39:251–9. 10.1007/s00259-011-1979-6 [Abstract] [CrossRef] [Google Scholar]
175. Rajagopalan V, Pioro EP. Comparing brain structural MRI and metabolic FDG-PET changes in patients with ALS-FTD: 'the chicken or the egg?' question. J Neurol Neurosurg Psychiatry (2015) 86:952–8. 10.1136/jnnp-2014-308239 [Abstract] [CrossRef] [Google Scholar]
176. Van Weehaeghe D, Ceccarini J, Delva A, Robberecht W, Van Damme P, Van Laere K. Prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis. J Nuclear Med. (2016) 57:1238–43. 10.2967/jnumed.115.166272 [Abstract] [CrossRef] [Google Scholar]
177. Cistaro A, Pagani M, Montuschi A, Calvo A, Moglia C, Canosa A, et al. . The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nuclear Med Mol Imag. (2014) 41:844–52. 10.1007/s00259-013-2667-5 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
178. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. (2004) 15:601–9. 10.1016/j.nbd.2003.12.012 [Abstract] [CrossRef] [Google Scholar]
179. Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. . Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS ONE (2012) 7:e52941. 10.1371/journal.pone.0052941 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
180. Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. NeuroImage Clin. (2015) 7:409–14. 10.1016/j.nicl.2015.01.009 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
181. Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius SM, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci. (2007) 255:17–22. 10.1016/j.jns.2007.01.057 [Abstract] [CrossRef] [Google Scholar]
182. Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A, Leigh PN. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain (2000) 123( Pt 11):2289–96. 10.1093/brain/123.11.2289 [Abstract] [CrossRef] [Google Scholar]
183. Douaud G, Filippini N, Knight S, Talbot K, Turner MR. Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain (2011) 134(Pt 12):3470–9. 10.1093/brain/awr279 [Abstract] [CrossRef] [Google Scholar]
184. Turner MR, Rabiner EA, Hammers A, Al-Chalabi A, Grasby PM, Shaw CE, et al. . [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain (2005) 128(Pt 4):896–905. 10.1093/brain/awh428 [Abstract] [CrossRef] [Google Scholar]
185. Jelsone-Swain LM, Fling BW, Seidler RD, Hovatter R, Gruis K, Welsh RC. Reduced interhemispheric functional connectivity in the motor cortex during rest in limb-onset amyotrophic lateral sclerosis. Front Syst Neurosci. (2010) 4:158. 10.3389/fnsys.2010.00158 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
186. Tedeschi G, Trojsi F, Tessitore A, Corbo D, Sagnelli A, Paccone A, et al. . Interaction between aging and neurodegeneration in amyotrophic lateral sclerosis. Neurobiol Aging (2012) 33:886–98. 10.1016/j.neurobiolaging.2010.07.011 [Abstract] [CrossRef] [Google Scholar]
187. Mohammadi B, Kollewe K, Samii A, Krampfl K, Dengler R, Munte TF. Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol. (2009) 217:147–53. 10.1016/j.expneurol.2009.01.025 [Abstract] [CrossRef] [Google Scholar]
188. Fekete T, Zach N, Mujica-Parodi LR, Turner MR. Multiple kernel learning captures a systems-level functional connectivity biomarker signature in amyotrophic lateral sclerosis. PLoS ONE (2013) 8:e85190. 10.1371/journal.pone.0085190 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
189. Trojsi F, Esposito F, de Stefano M, Buonanno D, Conforti FL, Corbo D, et al. . Functional overlap and divergence between ALS and bvFTD. Neurobiol Aging (2015) 36:413–23. 10.1016/j.neurobiolaging.2014.06.025 [Abstract] [CrossRef] [Google Scholar]
190. Agosta F, Canu E, Inuggi A, Chio A, Riva N, Silani V, et al. . Resting state functional connectivity alterations in primary lateral sclerosis. Neurobiol Aging (2014) 35:916–25. 10.1016/j.neurobiolaging.2013.09.041 [Abstract] [CrossRef] [Google Scholar]
191. Agosta F, Valsasina P, Absinta M, Riva N, Sala S, Prelle A, et al. . Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis. Cerebr Cortex (2011) 21:2291–8. 10.1093/cercor/bhr002 [Abstract] [CrossRef] [Google Scholar]
192. Zhou F, Xu R, Dowd E, Zang Y, Gong H, Wang Z. Alterations in regional functional coherence within the sensory-motor network in amyotrophic lateral sclerosis. Neurosci Lett. (2014) 558:192–6. 10.1016/j.neulet.2013.11.022 [Abstract] [CrossRef] [Google Scholar]
193. Agosta F, Canu E, Valsasina P, Riva N, Prelle A, Comi G, et al. . Divergent brain network connectivity in amyotrophic lateral sclerosis. Neurobiol Aging (2013) 34:419–27. 10.1016/j.neurobiolaging.2012.04.015 [Abstract] [CrossRef] [Google Scholar]
194. Luo C, Chen Q, Huang R, Chen X, Chen K, Huang X, et al. . Patterns of spontaneous brain activity in amyotrophic lateral sclerosis: a resting-state FMRI study. PLoS ONE (2012) 7:e45470. 10.1371/journal.pone.0045470 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
195. Tietz F HV, Prell T, Penzlin S, Ilse B, Bokemeyer M, et al. The resting state default mode network (DMN) is pathologically hyperactive in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2012) 13:171 10.3389/fnins.2016.00204 [CrossRef] [Google Scholar]
196. Heimrath J, Gorges M, Kassubek J, Muller HP, Birbaumer N, Ludolph AC, et al. . Additional resources and the default mode network: Evidence of increased connectivity and decreased white matter integrity in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:537–45. 10.3109/21678421.2014.911914 [Abstract] [CrossRef] [Google Scholar]
197. Chiò A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol. (2014) 13:1228–40. 10.1016/S1474-4422(14)70167-X [Abstract] [CrossRef] [Google Scholar]
198. Bede P. Deciphering neurodegeneration: A paradigm shift from focality to connectivity. Neurology (2017) 89:1758–9. 10.1212/WNL.0000000000004582 [Abstract] [CrossRef] [Google Scholar]
199. Turner MR, Kiernan MC. Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler. (2012) 13:245–50. 10.3109/17482968.2011.636050 [Abstract] [CrossRef] [Google Scholar]
200. Schoenfeld MA, Tempelmann C, Gaul C, Kuhnel GR, Duzel E, Hopf JM, et al. . Functional motor compensation in amyotrophic lateral sclerosis. J Neurol. (2005) 252:944–52. 10.1007/s00415-005-0787-y [Abstract] [CrossRef] [Google Scholar]
201. Konrad C, Jansen A, Henningsen H, Sommer J, Turski PA, Brooks BR, et al. . Subcortical reorganization in amyotrophic lateral sclerosis. Exp Brain Res. (2006) 172:361–9. 10.1007/s00221-006-0352-7 [Abstract] [CrossRef] [Google Scholar]
202. Konrad C, Henningsen H, Bremer J, Mock B, Deppe M, Buchinger C, et al. . Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res. (2002) 143:51–6. 10.1007/s00221-001-0981-9 [Abstract] [CrossRef] [Google Scholar]
203. Cosottini M, Pesaresi I, Piazza S, Diciotti S, Cecchi P, Fabbri S, et al. . Structural and functional evaluation of cortical motor areas in Amyotrophic Lateral Sclerosis. Exp Neurol. (2012) 234:169–80. 10.1016/j.expneurol.2011.12.024 [Abstract] [CrossRef] [Google Scholar]
204. Stanton BR, Williams VC, Leigh PN, Williams SC, Blain CR, Jarosz JM, et al. . Altered cortical activation during a motor task in ALS. Evidence for involvement of central pathways. J Neurol. (2007) 254:1260–7. 10.1007/s00415-006-0513-4 [Abstract] [CrossRef] [Google Scholar]
205. Poujois A, Schneider FC, Faillenot I, Camdessanche JP, Vandenberghe N, Thomas-Anterion C, et al. . Brain plasticity in the motor network is correlated with disease progression in amyotrophic lateral sclerosis. Hum Brain Map. (2013) 34:2391–401. 10.1002/hbm.22070 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
206. Goldstein LH, Newsom-Davis IC, Bryant V, Brammer M, Leigh PN, Simmons A. Altered patterns of cortical activation in ALS patients during attention and cognitive response inhibition tasks. J Neurol. (2011) 258:2186–98. 10.1007/s00415-011-6088-8 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
207. Witiuk K, Fernandez-Ruiz J, McKee R, Alahyane N, Coe BC, Melanson M, et al. . Cognitive deterioration and functional compensation in ALS measured with fMRI using an inhibitory task. J Neurosci. (2014) 34:14260–71. 10.1523/JNEUROSCI.1111-14.2014 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
208. Mohammadi B, Kollewe K, Cole DM, Fellbrich A, Heldmann M, Samii A, et al. . Amyotrophic lateral sclerosis affects cortical and subcortical activity underlying motor inhibition and action monitoring. Hum Brain Mapp. (2015) 36:2878–89. 10.1002/hbm.22814 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
209. Passamonti L, Fera F, Tessitore A, Russo A, Cerasa A, Gioia CM, et al. . Dysfunctions within limbic-motor networks in amyotrophic lateral sclerosis. Neurobiol Aging (2013) 34:2499–509. 10.1016/j.neurobiolaging.2013.05.016 [Abstract] [CrossRef] [Google Scholar]
210. Stoppel CM, Vielhaber S, Eckart C, Machts J, Kaufmann J, Heinze HJ, et al. . Structural and functional hallmarks of amyotrophic lateral sclerosis progression in motor- and memory-related brain regions. NeuroImage Clin. (2014) 5:277–90. 10.1016/j.nicl.2014.07.007 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
211. Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, et al. . Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2009) 10:131–46. 10.1080/17482960802654364 [Abstract] [CrossRef] [Google Scholar]
212. Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, D OB, et al. . Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. J Neurol Neurosurg Psychiatry (2011) 82:413–8. 10.1136/jnnp.2010.232637 [Abstract] [CrossRef] [Google Scholar]
213. Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. (2015) 262:1447–54. 10.1007/s00415-015-7731-6 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
214. Burke T, Elamin M, Galvin M, Hardiman O, Pender N. Caregiver burden in amyotrophic lateral sclerosis: a cross-sectional investigation of predictors. J Neurol. (2015) 262:1526–32. 10.1007/s00415-015-7746-z [Abstract] [CrossRef] [Google Scholar]
215. Andrews SC, Pavlis A, Staios M, Fisher F. Which behaviours? Identifying the most common and burdensome behaviour changes in amyotrophic lateral sclerosis. Psychol Health Med. (2017) 22:483–92. 10.1080/13548506.2016.1164871 [Abstract] [CrossRef] [Google Scholar]
216. Bock M, Duong YN, Kim A, Allen I, Murphy J, Lomen-Hoerth C. Progression and effect of cognitive-behavioral changes in patients with amyotrophic lateral sclerosis. Neurol Clin Pract. (2017) 7:488–98. 10.1212/CPJ.0000000000000397 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
217. Van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, Van der Graaff MM, et al. . Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology (2005) 65:1264–7. 10.1212/01.wnl.0000180717.29273.12 [Abstract] [CrossRef] [Google Scholar]
218. Hardiman O. Multidisciplinary care in ALS: expanding the team. Amyotroph Lateral Scler. (2012) 13:165. 10.3109/17482968.2012.657006 [Abstract] [CrossRef] [Google Scholar]
219. Desai J, Swash M. Extrapyramidal involvement in amyotrophic lateral sclerosis: backward falls and retropulsion. J Neurol Neurosurg Psychiatry (1999) 67:214–6. 10.1136/jnnp.67.2.214 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
220. Feron M, Couillandre A, Mseddi E, Termoz N, Abidi M, Bardinet E, et al. . Extrapyramidal deficits in ALS: a combined biomechanical and neuroimaging study. J Neurol. (2018). 10.1007/s00415-018-8964-y. [Epub ahead of print]. [Abstract] [CrossRef] [Google Scholar]
221. Chio A, Calvo A, Cammarosano S, Dematteis F, Artusi CA, Pagani M, et al. Extrapyramidal involvement in ALS: a prospective population-based study (P4.314). Neurology (2017) 79:1983–9. 10.1212/WNL.0b013e3182735d36. [CrossRef] [Google Scholar]
222. Pupillo E, Bianchi E, Messina P, Chiveri L, Lunetta C, Corbo M, et al. . Extrapyramidal and cognitive signs in amyotrophic lateral sclerosis: a population based cross-sectional study. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:324–30. 10.3109/21678421.2015.1040028 [Abstract] [CrossRef] [Google Scholar]
223. McCluskey L, Vandriel S, Elman L, Van Deerlin VM, Powers J, Boller A, et al. ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. Journal of the neurological Sciences (2014) 345:118–24. 10.1016/j.jns.2014.07.022 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
224. Giordana MT, Ferrero P, Grifoni S, Pellerino A, Naldi A, Montuschi A. Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review. Neurol Sci. (2011) 32:9–16. 10.1007/s10072-010-0439-6 [Abstract] [CrossRef] [Google Scholar]
225. Khan AM. Rare presentation of amyotrophic lateral sclerosis as frontotemporal dementia: a case report. Open Access J Toxicol. (2017) 1:555566 10.19080/OAJT.2017.01.555566 [CrossRef] [Google Scholar]
226. Turner MR, Goldacre R, Talbot K, Goldacre MJ. Psychiatric disorders prior to amyotrophic lateral sclerosis. Ann Neurol. (2016) 80:935–8. 10.1002/ana.24801 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
227. Qureshi AI, Wilmot G, Dihenia B, Schneider JA, Krendel DA. Motor neuron disease with parkinsonism. Arch Neurol. (1996) 53:987–91. 10.1001/archneur.1996.00550100061015 [Abstract] [CrossRef] [Google Scholar]
228. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. (2014) 13:1127–38. 10.1016/S1474-4422(14)70129-2 [Abstract] [CrossRef] [Google Scholar]
229. Cui B, Cui L, Liu M, Ma J, Fang J. Amyotrophic lateral sclerosis with frontotemporal dementia presented with prominent psychosis. Chin Med J. (2014) 127:3996–8. [Abstract] [Google Scholar]
230. Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, et al. . Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lateral Scler Frontotemporal Degener. (2015) 16:497–505. 10.3109/21678421.2015.1074700 [Abstract] [CrossRef] [Google Scholar]
231. Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology (2012) 79:1732–9. 10.1212/WNL.0b013e31826e9b1d [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
232. Bertrand A, Wen J, Rinaldi D, Houot M, Sayah S, Camuzat A, et al. . Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 years. JAMA Neurol. (2018) 75:236–45. 10.1001/jamaneurol.2017.4266 [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
233. Eisen A, Kiernan M, Mitsumoto H, Swash M. Amyotrophic lateral sclerosis: a long preclinical period? J Neurol Neurosurg Psychiatry (2014) 85:1232–8. 10.1136/jnnp-2013-307135 [Abstract] [CrossRef] [Google Scholar]
Articles from Frontiers in Neurology are provided here courtesy of Frontiers Media SA

Full text links 

Read article at publisher's site: https://doi.org/10.3389/fneur.2018.01005

Read article for free, from open access legal sources, via Unpaywall: https://www.frontiersin.org/articles/10.3389/fneur.2018.01005/pdfUnpaywall

Citations & impact 

Impact metrics

51
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/51671226
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/51671226

Article citations

Go to all (51) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.